Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

General Information

QRxPharma Limited
QRX
http://www.qrxpharma.com
Pharmaceuticals
5
164

Current Price Data+

Current Price Open High Low Last Close Volume Price Movement
$0.03 - - - $0.03 0 - ( No change )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Current Broker Consensus Recommendation

Strong Buy
20/08/2014
1

Company Overview

Business Description
QRxPharma Limited (QRX) is a commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and abuse prevention products. QRX conducts its operations in Australia.
Strategy Analysis
In 2012, QRX plan to implement pre-launch messaging strategy, identify key geographic areas of concentration, implement MoxDue pre-launch promotional message and begin recruitment of additional Actavis territory managers. Beyond 2012, QRX strategy is to expand the sales force to 150-200. QRxPharma reported net loss of $5.21m, up 7.87% for the half-year ended 31 December 2012. Revenue from ordinary activities were $2.24m, down 26.89% from last year. Basic and Diluted EPS were (3.6) cents compared to (4) cents last year. The net operating cash outflow was $6.04m compared to an outflow of $1.92m in the pcp. No dividend was declared.

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014 A -13.3 -8.5 0.0% 0.0 0.0 0.0% 0.0%
2013 A -10.1 -7.0 0.0% 0.0 0.0 0.0% 0.0%
2012 A -16.0 -11.2 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Acrux Limited (ACR) $114M 3.0384 -0.6024 0.2934 4.0774 10.2545 7.9282 11.68% 11.68% 11.68%
Mayne Pharma Group (MYX) $933M 1.0457 -0.1693 1.0423 37.8594 45.5769 22.3164 0.00% 0.00% 0.00%
QRxPharma (QRX) $5M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Starpharma (SPL) $209M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 0.50 0.00
Market 0.89 16.20 1.33 1.33
Sector 0.81 13.20 3.15 1.03

Directors

Name Position Start Date
Mr Bruce Alan Hancox Non-Executive Director 09/07/2014
Dr Richard Treagus Non-Executive Director 09/07/2014

Management

Name Position
Edward Rudnic Chief Executive Officer
Chris Campbell Chief Financial Officer,Company Secretary
Beth A Burnside Senior Vice President Regulatory Affairs and Compliance
M. Janette Dixon Vice President Global Business Development

Substantial Shareholders

Holding Name
20,854,104 (12.70%) Allan Gray Australia Pty Ltd
15,653,120 (9.53%) Walker Group Holdings Pty Limited

Calendar of Events

Date Event
24 February 2016 Report (Interim)
25 September 2015 Report (Annual)
26 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.